5. CONCLUSION
This study has demonstrated that there is no clinically significant difference in the levels of laboratory parameters, intensive care admission, intubation requirement, rate of complications and most importantly, survival rates in patients with CSD and those with cancer who are infected with SARS-CoV-2, except in Hb and ferritin levels. Additionally, in these patients, it was observed that SARS-CoV-2 infection had a clinically worse prognosis and fatal course compared to those of normal population. Therefore, these patients should adhere more strictly to general protection measures. It is recommended to plan the treatment of patients with cancer and CSD infected with SARS-CoV-2 based on a careful risk-benefit analysis by multidisciplinary teams.